<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tuberculosis infection (latent tuberculosis) in pregnancy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tuberculosis infection (latent tuberculosis) in pregnancy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tuberculosis infection (latent tuberculosis) in pregnancy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sylvia M LaCourse, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">C Fordham von Reyn, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 01, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3775731517"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tuberculosis (TB) terminology is inconsistent in the literature  (<a class="graphic graphic_table graphicRef132526" href="/z/d/graphic/132526.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. The following terms are used in this discussion:</p><p class="bulletIndent1"><span class="glyph">●</span>Tuberculosis infection (newer term for latent tuberculosis)</p><p class="bulletIndent1"><span class="glyph">●</span>Tuberculosis disease (newer term for active tuberculosis)</p><p></p><p>Prenatal care presents a unique opportunity for evaluation and management of TB infection (TBI) among individuals with risk of TB who may not otherwise present for medical care.</p><p>Organizations with published guidance for diagnosis and management of TBI include the United States Centers for Disease Control and Prevention (CDC), the United States National Tuberculosis Controllers Association (NTCA), the United States Department of Health and Human Services (DHHS), the American Thoracic Society (ATS), the Infectious Disease Society of America (IDSA), and the World Health Organization (WHO) [<a href="#rid2">2-6</a>].</p><p>Issues related to diagnosis and treatment of TBI in pregnant patients will be reviewed here, for infection that is presumed to be susceptible to <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> and/or <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>.</p><p>Issues related to the management of TB disease in pregnant patients are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8014.html" rel="external">"Tuberculosis disease (active tuberculosis) in pregnancy"</a>.)</p><p>Issues related to TB in children are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8007.html" rel="external">"Tuberculosis disease in children: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/135189.html" rel="external">"Tuberculosis disease in children: Treatment and prevention"</a> and  <a class="medical medical_review" href="/z/d/html/8020.html" rel="external">"Tuberculosis infection (latent tuberculosis) in children"</a>.)</p><p class="headingAnchor" id="H2416734346"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>TB terminology is inconsistent in the literature [<a href="#rid1">1</a>]. Relevant terms are defined in the table  (<a class="graphic graphic_table graphicRef132526" href="/z/d/graphic/132526.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H2482955624"><span class="h1">NATURAL HISTORY OF TB IN PREGNANCY</span><span class="headingEndMark"> — </span>TBI is caused by inhalation of viable bacilli, which may persist in a clinically inactive state (known as TBI, or latent TBI) or progress to TB disease. While we continue to expand our understanding of the dynamic and continuous spectrum of TBI to TB disease, for the purposes of this discussion we define TBI as presence of evidence for TB infection, in the absence of clinical, radiographic, or microbiological evidence of TB disease [<a href="#rid7">7</a>].</p><p>Individuals with TBI are asymptomatic and not infectious. TB bacilli remain viable and may reactivate, causing active symptomatic TB disease, which can be transmitted via airborne spread. The natural history of TB is discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/8023.html" rel="external">"Tuberculosis: Natural history, microbiology, and pathogenesis"</a>.)</p><p>Pregnancy has not been definitively proven to influence the pathogenesis of TB or the likelihood of progression from TB infection to active disease, nor has it been shown to affect the response to treatment [<a href="#rid8">8</a>]. However, multiple cohort studies have found higher incidence of TB disease among pregnant and/or postpartum individuals compared with nonpregnant individuals:</p><p class="bulletIndent1"><span class="glyph">●</span>One study including more than 192,000 pregnant people in the United Kingdom between 1996 and 2008 noted a higher incidence of TB diagnosis among postpartum individuals compared with nonpregnant individuals (incidence rate ratio [IRR] 1.95, 95% CI 1.24-3.07) but no significant increase in the incidence of TB diagnosis during pregnancy (IRR 1.29, 95% CI 0.82-2.03) [<a href="#rid9">9</a>]; the authors hypothesized these observations may have been due in part to delays in diagnosis of TB disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study of more than 649,000 people ages 14 to 49 years who gave birth in Sweden between 2005 and 2013, an increased incidence of TB disease during pregnancy (IRR 1.4, 95% CI 1.1-1.7) and during the first six months postpartum (IRR 1.9, 95% CI 1.5-2.5) was observed, compared with nonpregnant periods [<a href="#rid10">10</a>].</p><p></p><p class="headingAnchor" id="H557215887"><span class="h1">SCREENING FOR TB INFECTION</span></p><p class="headingAnchor" id="H946581867"><span class="h2">Whom to test</span><span class="headingEndMark"> — </span>Testing asymptomatic patients for TBI during pregnancy is warranted for patients with significant risk factors for TB and progression to TB disease during pregnancy [<a href="#rid4">4,11</a>]; these include:</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnant patients with recent contact with a patient with infectious active respiratory TB.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnant patients with human immunodeficiency (HIV) infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnant patients with other significant immunosuppression – This includes patients receiving medications such as corticosteroids (≥15 mg/day of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> for ≥1 month), immunosuppressive therapy, or tumor necrosis factor-alpha inhibitors as well as patients with major immunocompromising conditions (eg, lymphoma, leukemia, head and neck cancer, solid organ transplant).</p><p></p><p>Issues related to indications for TBI screening are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)", section on 'Indications for TBI testing'</a>.)</p><p>A positive test for TBI (see below) should prompt an evaluation for TB disease (see <a class="local">'Diagnostic evaluation after positive test'</a> below); pregnant patients with TB disease should be treated immediately. (See  <a class="medical medical_review" href="/z/d/html/8014.html" rel="external">"Tuberculosis disease (active tuberculosis) in pregnancy"</a>.)</p><p>If TB disease is excluded, decisions regarding timing of treatment for TBI are based on individual circumstances. (See <a class="local">'Treatment'</a> below.)</p><p>For patients with TB risk factors not included above, TBI treatment can be delayed until two to three months after delivery to minimize risk of adverse drug effects related to treatment. (See  <a class="medical medical_review" href="/z/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)"</a>.)</p><p>If indicated, TBI testing prior to pregnancy is preferred (if feasible); this allows opportunity for counseling about the risk of becoming pregnant with TBI as well as the potential opportunity to treat TBI before pregnancy [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H1917434883"><span class="h2">How to test</span><span class="headingEndMark"> — </span>The diagnosis of TBI is established by demonstrating an immune response to <em>Mycobacterium tuberculosis</em> antigens and excluding TB disease. (See  <a class="medical medical_review" href="/z/d/html/8014.html" rel="external">"Tuberculosis disease (active tuberculosis) in pregnancy"</a>.)</p><p>Available tests to detect the immune response to TB antigens include the <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> (TST) and interferon-gamma release assays (IGRAs). Both tests evaluate cell-mediated immunity. The TST measures immune sensitization (type IV or delayed-type hypersensitivity) to mycobacterial protein antigens that occurs following exposure to (and infection by) mycobacteria, while IGRAs measure the release of interferon-gamma following stimulation by antigens unique to <em>M. tuberculosis</em>. (See  <a class="medical medical_review" href="/z/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)"</a>.)</p><p>Both TST and IGRAs can be performed safely in pregnant patients, and either test may be used [<a href="#rid11">11,13-20</a>]. Some data suggest that both of these tests may be affected by pregnancy [<a href="#rid18">18-20</a>].</p><p>Definitions of positive TST are summarized in the table  (<a class="graphic graphic_table graphicRef67357" href="/z/d/graphic/67357.html" rel="external">table 2</a>). Additional issues related to TST and IGRA interpretation, including causes of false-negative and false-positive tests, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15352.html" rel="external">"Use of interferon-gamma release assays for diagnosis of tuberculosis infection (tuberculosis screening) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/8005.html" rel="external">"Use of the tuberculin skin test for diagnosis of tuberculosis infection (tuberculosis screening) in adults"</a>.)</p><p class="headingAnchor" id="H1494910621"><span class="h2">Diagnostic evaluation after positive test</span><span class="headingEndMark"> — </span>Patients with a positive TST or IGRA must undergo clinical evaluation to rule out TB disease. This includes evaluation for symptoms (eg, fever, cough, weight loss [or lower than expected weight gain for pregnancy]) and radiographic examination of the chest (with appropriate shielding), regardless of gestational age. (See  <a class="medical medical_review" href="/z/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)", section on 'Excluding TB disease'</a>.)</p><p>Patients with a positive TST or IGRA with no evidence of TB disease may be presumed to have TBI and should be managed as discussed below.</p><p class="headingAnchor" id="H2169059547"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Patients with TBI are asymptomatic and not infectious. There is no risk for vertical transmission of TBI.</p><p class="headingAnchor" id="H1365328701"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H970708760"><span class="h2">General principles</span><span class="headingEndMark"> — </span>Our approach consists of shared decision-making; this includes discussion about the risks and benefits of TB preventive therapy during pregnancy relative to the risk of progression to TB disease during pregnancy and the early postpartum period. Pregnant people with HIV residing in higher TB incidence settings are at higher risk of developing TB than those residing in lower-incidence settings; therefore, the discussion should take into account the risk of developing of TB disease.</p><p>All patients diagnosed with TBI prior to pregnancy and started on treatment for an appropriate indication should continue TBI treatment during pregnancy; the regimen should be modified (if necessary) to a regimen suitable for pregnancy, described below [<a href="#rid11">11,21</a>].</p><p>For patients with significant immunosuppression (apart from HIV infection, which is discussed below), the decision to treat during pregnancy or defer until after delivery should be based on individual clinical circumstances including the degree of immunosuppression.</p><p class="headingAnchor" id="H195427254"><span class="h2">Patients without HIV infection</span></p><p class="headingAnchor" id="H2794009860"><span class="h3">Timing of treatment</span><span class="headingEndMark"> — </span>Our approach to timing of TBI treatment in pregnant patients without HIV infection is as follows  (<a class="graphic graphic_algorithm graphicRef139994" href="/z/d/graphic/139994.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Positive screening test for TBI</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Recent exposure to a patient with active respiratory TB</strong> – We initiate TBI treatment promptly during pregnancy (even during the first trimester), given increased risk of progression to TB disease after a recent exposure. (See <a class="local">'Selecting a regimen'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Recent (within two years) conversion of a test for TB infection from negative to positive</strong> – We initiate TBI treatment promptly during pregnancy (even during the first trimester), given increased risk of progression to TB disease due to presumed recent infection. (See <a class="local">'Selecting a regimen'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>No recent exposure to a patient with untreated active respiratory TB and no recent TB infection test conversion</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Presence of immunosuppression</strong> (see <a class="local">'Whom to test'</a> above) – We initiate TBI treatment promptly during pregnancy (even during the first trimester), given increased risk of progression to TB disease due to immunosuppression. (See <a class="local">'Selecting a regimen'</a> below.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Absence of immunosuppression</strong> – We defer TBI treatment until two to three months after delivery [<a href="#rid2">2</a>], to minimize the risk of adverse drug effects and adverse pregnancy outcomes associated with TBI treatment during pregnancy [<a href="#rid22">22-24</a>]. In such cases, close follow-up is required [<a href="#rid25">25</a>]. After delivery, such patients should have follow-up evaluation for active disease (including chest radiograph) to confirm that TB disease did not develop in the interval since diagnosis of TBI and the time that treatment for TBI begins. (See  <a class="medical medical_review" href="/z/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)", section on 'Excluding TB disease'</a> and  <a class="medical medical_review" href="/z/d/html/8017.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults without HIV infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Negative screening test for TBI</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Recent exposure to a patient with active respiratory TB</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Presence of immunosuppression</strong> – We initiate TBI treatment promptly during pregnancy (even during the first trimester), given increased risk of progression to TB disease. (See <a class="local">'Selecting a regimen'</a> below.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Absence of immunosuppression</strong> – No role for TBI treatment at this time. However, the patient should be retested 10 weeks after the last infectious exposure to see if they have become infected.</p><p></p><p class="headingAnchor" id="H4086930205"><span class="h3">Selecting a regimen</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Available regimens</strong> - Regimens for treatment of TBI in pregnancy include  (<a class="graphic graphic_table graphicRef73637" href="/z/d/graphic/73637.html" rel="external">table 3</a>) [<a href="#rid2">2</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">Rifampin</a> (daily for four months; abbreviation 4R)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">Isoniazid</a> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> (daily for three months; abbreviation 3HR)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">Isoniazid</a> (daily for nine or six months; abbreviation 9H or 6H)</p><p></p><p class="bulletIndent1">For treatment of pregnant patients with TBI in the absence of HIV infection, we suggest a rifamycin-based regimen over <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> monotherapy given shorter treatment duration, higher rates of treatment completion, and decreased risk of hepatotoxicity.</p><p></p><p class="bulletIndent1">Patients on regimens including <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> should also receive <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">pyridoxine</a> supplementation (25 to 50 mg daily) given to reduce the risk of isoniazid-induced peripheral neuropathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy for rifamycin-based regimens</strong> – Support for use of 4R and 3HR in pregnancy is based on extrapolation of data from studies in nonpregnant patients. Among nonpregnant adults, 4R has been shown to be noninferior to <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> (daily for nine months) for prevention of TB disease; it is also associated with a higher rate of treatment completion and lower rate of hepatotoxicity [<a href="#rid26">26</a>]. 3HR has similar efficacy and hepatotoxicity to that of isoniazid administered for six months [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/z/d/html/8017.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults without HIV infection", section on 'Rifampin (4R)'</a> and  <a class="medical medical_review" href="/z/d/html/8011.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults with HIV infection", section on 'Isoniazid and rifampin (3HR)'</a>.)</p><p></p><p class="bulletIndent1">Neither the three-month weekly <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> and <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">rifapentine</a> (abbreviation 3HP) regimen nor the one-month daily isoniazid and rifapentine (abbreviation 1HP) regimen are recommended for individuals who are pregnant or expecting to become pregnant during the treatment period, due to limited safety data for rifapentine in pregnancy [<a href="#rid28">28</a>]. One clinical trial evaluating the pharmacokinetics and safety of 3HP in 50 pregnant patients (including 20 with HIV on efavirenz-based antiretroviral therapy [ART]) did not identify any drug-related serious adverse events [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy for </strong><a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a><strong> monotherapy </strong>– If isoniazid is used, we favor daily administration for nine months given its established efficacy based on data in nonpregnant patients. Isoniazid daily for six months provides some protection; in the setting of difficulty with adherence, providers may prefer to concentrate efforts in ensuring six months of therapy. This approach is favored by the World Health Organization (WHO). However, regimens shorter than nine months should not be used for patients with fibrotic lesions on chest radiograph. (See  <a class="medical medical_review" href="/z/d/html/8017.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults without HIV infection", section on 'Isoniazid monotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rifamycin nitrosamine impurities </strong>– In August 2020, the US Food and Drug Administration (FDA) announced detection of nitrosamine impurities in samples of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> [<a href="#rid30">30</a>]. Some such compounds have been implicated as possible carcinogens in long-term animal studies, with toxicity largely related to cumulative exposure. Because the risks from TB appear to be greater than those from cancer, and the risks for serious toxicity such as isoniazid-induced hepatitis may be substantial with alternative regimens, the United States Centers for Disease Control and Prevention (CDC) and FDA recommend the use of rifampin continue for treatment of TBI. This should be done only following individual patient discussion of benefits, risks, and alternatives, which may include deferral of treatment altogether.</p><p></p><p class="headingAnchor" id="H3575142802"><span class="h2">Patients with HIV infection</span></p><p class="headingAnchor" id="H3692317708"><span class="h3">Settings with TB transmission &lt;500 per 100,000</span></p><p class="headingAnchor" id="H1986433788"><span class="h4">Timing of treatment</span><span class="headingEndMark"> — </span>Our approach to management of TBI in pregnant patients with HIV infection is as follows  (<a class="graphic graphic_algorithm graphicRef139995" href="/z/d/graphic/139995.html" rel="external">algorithm 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recent exposure to a patient with untreated active respiratory TB</strong> – We initiate TBI treatment promptly during pregnancy (even during the first trimester), given increased risk of progression to TB disease after a recent exposure. (See <a class="local">'Selecting a regimen'</a> below and  <a class="medical medical_review" href="/z/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)", section on 'Individuals with recent exposure (close and casual contacts)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recent (within two years) conversion of a test for TB infection to positive</strong> – We initiate TBI treatment promptly during pregnancy (even during the first trimester), given increased risk of progression to TB disease. (See <a class="local">'Selecting a regimen'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No recent exposure to a patient with untreated active respiratory TB and no recent TB infection test conversion</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with HIV infection on antiretroviral therapy</strong> – We defer TBI treatment until two to three months after delivery; this approach is in alignment with the CDC guidelines, which recommend treatment can be delayed for two to three months in pregnancy for patients at lower risk of progression to TB disease [<a href="#rid2">2</a>], and the Department of Health and Human Services guidelines for people with HIV, which state that treatment may be delayed until after delivery [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent2">This approach to defer treatment until after delivery is supported by a 2019 study demonstrating more frequent adverse pregnancy outcomes among pregnant patients in eight countries with high TB incidence treated with <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> during pregnancy than among patients treated three months after delivery [<a href="#rid23">23</a>]. The study included more than 900 participants with HIV (CD4 count 351 to 670 cells/mm<sup>3</sup> on antiretroviral therapy [ART]) randomly assigned to initiate TBI treatment with isoniazid immediately during pregnancy or defer treatment until 12 weeks after delivery. Patients in the first trimester and those with recent TB exposure were excluded. Mothers and infants were followed for 48 weeks after delivery. The incidence of TB was comparable between the groups (0.60 versus 0.59 per 100 person-years); however, the composite adverse pregnancy outcome (stillbirth or spontaneous abortion, low birth weight, preterm delivery, or congenital anomalies) was observed more frequently among patients in the immediate treatment group than in the deferred group (23.6 versus 17.0 percent; difference 6.7, 95% CI 0.8-11.9). The rate of hepatotoxicity was similar between the groups (6.2 versus 7.2 percent; relative difference -1.0, 95% CI -4.3 to 2.3). The risk of adverse pregnancy outcomes associated with isoniazid appears to be impacted by gestational age at exposure, with earlier exposure more associated with adverse pregnancy outcomes.</p><p></p><p class="bulletIndent2">Our approach to management of pregnant patients with HIV differs from the WHO 2020 TBI statement, which favors TBI treatment during pregnancy, regardless of recent exposure [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with HIV infection not on antiretroviral therapy</strong> – We initiate ART promptly; the risk of progression from TBI to TB disease in individuals on ART is significantly decreased [<a href="#rid4">4,31</a>]. Issues related to management of ART in pregnancy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15799.html" rel="external">"Antiretroviral selection and management in pregnant individuals with HIV in resource-rich settings"</a>.)</p><p></p><p class="bulletIndent2">Data to guide TBI management for pregnant patients with HIV who are not on ART are limited, and there is no consensus on the optimal approach. Pregnant people with HIV should receive ART, for their own health as well as for reducing the risk of perinatal HIV transmission.</p><p></p><p class="bulletIndent2">Pending further study, we favor initiation of TBI treatment during pregnancy for all patients with HIV who are not on ART; other experts favor initiation of TBI treatment during pregnancy only for those with CD4 count ≤200 cells/mm<sup>3</sup> (with deferral of treatment until two to three months after delivery for those with CD4 count &gt;200 cells/mm<sup>3</sup>) [<a href="#rid32">32</a>].</p><p></p><p class="headingAnchor" id="H2963997394"><span class="h4">Selecting a regimen</span><span class="headingEndMark"> — </span>In settings with TB disease incidence &lt;500 per 100,000, pregnant patients with HIV may be treated with the same TBI regimens as for pregnant patients without HIV infection (see <a class="local">'Selecting a regimen'</a> above); however, special consideration must be given to potential drug-drug interactions for patients receiving ART, especially with rifamycins. (See  <a class="medical medical_review" href="/z/d/html/8011.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults with HIV infection", section on 'Drug interactions: ART and rifamycins'</a>.)</p><p class="headingAnchor" id="H545107529"><span class="h3">Settings with TB transmission ≥500 per 100,000</span><span class="headingEndMark"> — </span>In settings with high TB transmission (incidence ≥500 per 100,000)  (<a class="graphic graphic_table graphicRef129995" href="/z/d/graphic/129995.html" rel="external">table 4</a>), the WHO recommends that people with HIV and a positive or unknown test for TB infection be treated with <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> for at least 36 months [<a href="#rid31">31</a>]; however, the regional TB transmission level is not always known. In general, we support the use of extended isoniazid (≥36 months) for settings with high TB incidence. This is discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/8011.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults with HIV infection", section on 'Settings with high TB transmission rates (≥500 per 100,000)'</a>.)</p><p class="headingAnchor" id="H236064035"><span class="h1">MONITORING DURING TREATMENT</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> − Pregnancy and the early postpartum period may confer increased risk for isoniazid-induced hepatotoxicity [<a href="#rid22">22,33-35</a>]. Other side effects of <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> include rashes, neuropsychiatric disturbances including depression, mania, memory loss and/or psychosis, pellagra, peripheral neuritis, and seizures.</p><p></p><p class="bulletIndent1">Adverse effects due to <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> include hepatitis, thrombocytopenia, hemolytic anemia, fever, and rash. (See  <a class="medical medical_review" href="/z/d/html/491.html" rel="external">"Rifamycins (rifampin, rifabutin, rifapentine)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Baseline evaluation</strong> − Pregnant patients and postpartum patients within three months of delivery should have baseline liver function testing (serum transaminases and bilirubin) prior to initiation of TBI treatment. Additional evaluation should include testing for HIV and hepatitis B and C as well as general evaluation for chronic liver disease, alcohol use, and exposure to other hepatotoxins.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring during treatment</strong> − In the absence of evidence for underlying liver disease, initiation of antituberculous drugs should be followed by monthly evaluation for symptoms of hepatitis, clinical examination, and liver function testing. In the setting of liver disease or abnormal liver function tests, more frequent monitoring may be warranted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient education</strong> − In addition, patients on antituberculous drugs should be educated about the symptoms of hepatitis and instructed to stop the medication should such symptoms occur and to seek prompt evaluation of symptoms to reduce risk for progression to severe disease [<a href="#rid36">36</a>]. Symptoms include anorexia, nausea, vomiting, dark urine, icterus, rash, persistent paresthesias of the hands and feet, persistent fatigue, weakness or fever lasting three or more days, abdominal pain (particularly right upper quadrant discomfort), easy bruising or bleeding, or arthralgias.</p><p></p><p>Issues related to regimen adjustments and hepatotoxicity should be addressed as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection", section on 'Regimen adjustments for drug intolerance'</a>.)</p><p class="headingAnchor" id="H3250441027"><span class="h1">BREASTFEEDING</span><span class="headingEndMark"> — </span>Breastfeeding is not contraindicated among patients on treatment for TBI with first-line agents [<a href="#rid37">37</a>]. The small concentrations of <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> found in breastmilk do not produce toxic effects in the nursing infant [<a href="#rid6">6,11,38,39</a>]. As such, these small concentrations also do not provide effective treatment for TBI in a nursing infant. Breastfed infants whose mothers are taking isoniazid do not require <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">pyridoxine</a> supplementation (unless the infant is also receiving isoniazid themselves) [<a href="#rid37">37</a>]. Rifamycins can cause orange discoloration of body fluids including breastmilk, which is expected and considered harmless to patients and their nursing infants.</p><p>Decisions about breastfeeding with second-line agents should be made in consultation with an expert. (See  <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">"Treatment of drug-resistant pulmonary tuberculosis in adults"</a>.)</p><p class="headingAnchor" id="H771444209"><span class="h1">PATIENTS WISHING TO AVOID OR TERMINATE PREGNANCY</span><span class="headingEndMark"> — </span>Rifamycins are potent inducers of hepatic metabolism of hormonal contraceptives (specifically progestin-only pills, combined hormonal contraception [pill, patch, ring], and implants), which can lead to significant reductions in concentrations (and therapeutic failure). In addition, rifamycins may decrease the concentrations of <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a> (used in medication abortions) reducing its effectiveness. This effect can last up to two weeks after rifamycin discontinuation.</p><p>Patients on rifamycins who are using these forms of contraception should receive counseling regarding use of alternative methods. (See  <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a> and  <a class="medical medical_review" href="/z/d/html/5475.html" rel="external">"Emergency contraception"</a>.)</p><p class="headingAnchor" id="H1451202998"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111822.html" rel="external">"Society guideline links: Diagnosis and treatment of tuberculosis"</a>.)</p><p class="headingAnchor" id="H1354758359"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural history of TB in pregnancy</strong> − (See <a class="local">'Natural history of TB in pregnancy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Natural history</strong> − Tuberculosis (TB) infection (TBI) is caused by inhalation of viable bacilli, which may persist in an inactive state (known as TB infection or latent TBI) or progress to TB disease. Individuals with TBI are asymptomatic and not contagious. Latent TB bacilli remain viable and may reactivate, causing active symptomatic TB disease, which can be transmitted via airborne spread.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Influence of pregnancy</strong> − Pregnancy has not been definitively proven to influence the pathogenesis of TB or the likelihood of progression from latent infection to active disease; however, multiple cohort studies have found higher incidence of TB disease among postpartum individuals compared with nonpregnant individuals.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Whom to test</strong> – Screening for TBI during pregnancy should be pursued for patients with significant risk factors for progression to active disease during pregnancy; these include patients with recent contact with a patient with untreated active respiratory TB, patients with HIV, and patients with other significant immunosuppression. (See <a class="local">'Whom to test'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>How to test</strong> – Diagnostic tools for TBI include tuberculin skin testing (TST) and interferon-gamma release assays (IGRAs). Definitions of positive TST are summarized in the table  (<a class="graphic graphic_table graphicRef67357" href="/z/d/graphic/67357.html" rel="external">table 2</a>). Patients with a positive TST or IGRA must undergo clinical evaluation to rule out TB disease; this includes evaluation for symptoms (eg, fever, cough, weight loss [or, in pregnancy, lower than expected weight gain]) and radiographic examination of the chest (with appropriate shielding), regardless of gestational age. (See <a class="local">'How to test'</a> above and <a class="local">'Diagnostic evaluation after positive test'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment approach</strong> − The potential risks of adverse pregnancy outcomes associated with TB preventive therapy during pregnancy must be weighed against the potential risks of progression to TB disease during pregnancy and the early postpartum period. Pregnant people with HIV residing in higher TB incidence settings are at higher risk of developing TB than those residing in lower-incidence settings; thus, discussion about the benefits and risks of initiating versus delaying to postpartum should take into account the risk of developing of TB disease. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients without HIV</strong> − Our approach is summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef139994" href="/z/d/graphic/139994.html" rel="external">algorithm 1</a>). For most pregnant patients without HIV, we suggest deferral of TBI treatment until two to three months after delivery (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We suggest initiation of treatment promptly during pregnancy (even in the first trimester) for patients with recent contact with a patient with untreated active respiratory TB, recent TBI test conversion, or significant immunosuppression (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Patients without HIV infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with HIV in low-TB transmission settings </strong>– Our approach is summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef139995" href="/z/d/graphic/139995.html" rel="external">algorithm 2</a>). For most pregnant patients with HIV on antiretroviral therapy (ART) in low-TB transmission settings, we suggest deferral of TBI treatment until two to three months after delivery (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We suggest initiation of treatment promptly during pregnancy (even during the first trimester) for patients with recent contact with a patient with untreated active respiratory TB, recent TBI test conversion, or patients who are not on ART (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Patients with HIV infection'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Regimen selection</strong> – For treatment of patients in the preceding two categories, we suggest a rifamycin-based regimen over <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> monotherapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), given the efficacy, favorable treatment completion rates, and relatively low hepatotoxicity rates of rifamycin-based regimens  (<a class="graphic graphic_table graphicRef73637" href="/z/d/graphic/73637.html" rel="external">table 3</a>). (See <a class="local">'Selecting a regimen'</a> above and <a class="local">'Settings with TB transmission &lt;500 per 100,000'</a> above.)</p><p></p><p class="bulletIndent3">Consideration must be given to potential drug-drug interactions for patients receiving ART and rifamycins. In addition, nitrosamine contamination must be considered in the risk-benefit analysis for any rifampin-based regimen. (See  <a class="medical medical_review" href="/z/d/html/8011.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults with HIV infection", section on 'Drug interactions: ART and rifamycins'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with HIV in high-TB transmission settings</strong> − For pregnant patients with HIV in high-TB transmission settings  (<a class="graphic graphic_table graphicRef129995" href="/z/d/graphic/129995.html" rel="external">table 4</a>), we suggest TBI treatment during pregnancy with daily <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> for 36 months (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Settings with TB transmission ≥500 per 100,000'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> − Issues related to baseline evaluation and monitoring are summarized above. (See <a class="local">'Monitoring during treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breastfeeding</strong> − Issues related to breastfeeding during TBI treatment are summarized above. (See <a class="local">'Breastfeeding'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Behr MA, Kaufmann E, Duffin J, et al. Latent Tuberculosis: Two Centuries of Confusion. Am J Respir Crit Care Med 2021; 204:142.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Treatment for TB During Pregnancy. https://www.cdc.gov/tb/topic/treatment/pregnancy.htm (Accessed on August 15, 2022).</li><li class="breakAll">TB Controllers. A GUIDE FOR HEALTH CARE PROVIDERS AND PUBLIC HEALTH PROGRAMS - Testing and Treatment of Latent Tuberculosis Infection in the United States: Clinical Recommendations. http://www.tbcontrollers.org/docs/resources/tb-infection/LTBI_Clinical_Recommendations_Version_002052021.pdf (Accessed on August 15, 2022).</li><li class="breakAll">Clinicalinfo.hiv.gov. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines (Accessed on August 15, 2022).</li><li class="breakAll">World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. https://apps.who.int/iris/handle/10665/331170 (Accessed on August 15, 2022).</li><li><a class="nounderline abstract_t">Sterling TR, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep 2020; 69:1.</a></li><li><a class="nounderline abstract_t">Drain PK, Bajema KL, Dowdy D, et al. Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. Clin Microbiol Rev 2018; 31.</a></li><li><a class="nounderline abstract_t">Miele K, Bamrah Morris S, Tepper NK. Tuberculosis in Pregnancy. Obstet Gynecol 2020; 135:1444.</a></li><li><a class="nounderline abstract_t">Zenner D, Kruijshaar ME, Andrews N, Abubakar I. Risk of tuberculosis in pregnancy: a national, primary care-based cohort and self-controlled case series study. Am J Respir Crit Care Med 2012; 185:779.</a></li><li><a class="nounderline abstract_t">Jonsson J, Kühlmann-Berenzon S, Berggren I, Bruchfeld J. Increased risk of active tuberculosis during pregnancy and postpartum: a register-based cohort study in Sweden. Eur Respir J 2020; 55.</a></li><li><a class="nounderline abstract_t">Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000; 49:1.</a></li><li><a class="nounderline abstract_t">Boggess KA, Myers ER, Hamilton CD. Antepartum or postpartum isoniazid treatment of latent tuberculosis infection. Obstet Gynecol 2000; 96:757.</a></li><li><a class="nounderline abstract_t">Present PA, Comstock GW. Tuberculin sensitivity in pregnancy. Am Rev Respir Dis 1975; 112:413.</a></li><li><a class="nounderline abstract_t">Mazurek GH, Jereb J, Lobue P, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54:49.</a></li><li><a class="nounderline abstract_t">Lighter-Fisher J, Surette AM. Performance of an interferon-gamma release assay to diagnose latent tuberculosis infection during pregnancy. Obstet Gynecol 2012; 119:1088.</a></li><li><a class="nounderline abstract_t">Worjoloh A, Kato-Maeda M, Osmond D, et al. Interferon gamma release assay compared with the tuberculin skin test for latent tuberculosis detection in pregnancy. Obstet Gynecol 2011; 118:1363.</a></li><li><a class="nounderline abstract_t">Jonnalagadda S, Lohman Payne B, Brown E, et al. Latent tuberculosis detection by interferon γ release assay during pregnancy predicts active tuberculosis and mortality in human immunodeficiency virus type 1-infected women and their children. J Infect Dis 2010; 202:1826.</a></li><li><a class="nounderline abstract_t">Weinberg A, Aaron L, Montepiedra G, et al. Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV. Clin Infect Dis 2021; 73:e3555.</a></li><li><a class="nounderline abstract_t">Kaplan SR, Escudero JN, Mecha J, et al. Interferon Gamma Release Assay and Tuberculin Skin Test Performance in Pregnant Women Living With and Without HIV. J Acquir Immune Defic Syndr 2022; 89:98.</a></li><li><a class="nounderline abstract_t">Bhosale R, Alexander M, Deshpande P, et al. Stages of pregnancy and HIV affect diagnosis of tuberculosis infection and Mycobacterium tuberculosis (MTB)-induced immune response: Findings from PRACHITi, a cohort study in Pune, India. Int J Infect Dis 2021; 112:205.</a></li><li><a class="nounderline abstract_t">Bothamley G. Drug treatment for tuberculosis during pregnancy: safety considerations. Drug Saf 2001; 24:553.</a></li><li><a class="nounderline abstract_t">Franks AL, Binkin NJ, Snider DE Jr, et al. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep 1989; 104:151.</a></li><li><a class="nounderline abstract_t">Gupta A, Montepiedra G, Aaron L, et al. Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. N Engl J Med 2019; 381:1333.</a></li><li><a class="nounderline abstract_t">Moro RN, Scott NA, Vernon A, et al. Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials. Ann Am Thorac Soc 2018; 15:570.</a></li><li><a class="nounderline abstract_t">Cruz CA, Caughey AB, Jasmer R. Postpartum follow-up of a positive purified protein derivative (PPD) among an indigent population. Am J Obstet Gynecol 2005; 192:1455.</a></li><li><a class="nounderline abstract_t">Menzies D, Adjobimey M, Ruslami R, et al. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N Engl J Med 2018; 379:440.</a></li><li><a class="nounderline abstract_t">Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337:801.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2011; 60:1650.</a></li><li><a class="nounderline abstract_t">Mathad JS, Savic R, Britto P, et al. Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women. Clin Infect Dis 2022; 74:1604.</a></li><li class="breakAll">US Food and Drug Administration. FDA Updates and Press Announcements on Nitrosamines in Rifampin and Rifapentine. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-nitrosamines-rifampin-and-rifapentine (Accessed on September 06, 2022).</li><li><a class="nounderline abstract_t">Middelkoop K, Bekker LG, Myer L, et al. Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township. Am J Respir Crit Care Med 2010; 182:1080.</a></li><li><a class="nounderline abstract_t">Day JH, Charalambous S, Fielding KL, et al. Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa. Int J Tuberc Lung Dis 2006; 10:523.</a></li><li><a class="nounderline abstract_t">Moulding TS, Redeker AG, Kanel GC. Twenty isoniazid-associated deaths in one state. Am Rev Respir Dis 1989; 140:700.</a></li><li><a class="nounderline abstract_t">Snider DE Jr, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992; 145:494.</a></li><li><a class="nounderline abstract_t">Knight M, Kurinczuk JJ, Nelson-Piercy C, et al. Tuberculosis in pregnancy in the UK. BJOG 2009; 116:584.</a></li><li><a class="nounderline abstract_t">Marks SM, Mase SR, Morris SB. Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis. Clin Infect Dis 2017; 64:1670.</a></li><li class="breakAll">American Academy of Pediatrics. Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32 ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021.</li><li class="breakAll">Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk, 7th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2005.</li><li><a class="nounderline abstract_t">Snider DE Jr, Powell KE. Should women taking antituberculosis drugs breast-feed? Arch Intern Med 1984; 144:589.</a></li></ol></div><div id="topicVersionRevision">Topic 135001 Version 3.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33761302" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Latent Tuberculosis: Two Centuries of Confusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33761302" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Latent Tuberculosis: Two Centuries of Confusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33761302" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Latent Tuberculosis: Two Centuries of Confusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33761302" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Latent Tuberculosis: Two Centuries of Confusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33761302" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Latent Tuberculosis: Two Centuries of Confusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32053584" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30021818" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32459437" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Tuberculosis in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22161161" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Risk of tuberculosis in pregnancy: a national, primary care-based cohort and self-controlled case series study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31862768" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Increased risk of active tuberculosis during pregnancy and postpartum: a register-based cohort study in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10881762" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11042314" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Antepartum or postpartum isoniazid treatment of latent tuberculosis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1172402" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Tuberculin sensitivity in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16357824" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22569120" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Performance of an interferon-gamma release assay to diagnose latent tuberculosis infection during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22105266" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Interferon gamma release assay compared with the tuberculin skin test for latent tuberculosis detection in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21067370" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Latent tuberculosis detection by interferonγrelease assay during pregnancy predicts active tuberculosis and mortality in human immunodeficiency virus type 1-infected women and their children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32720695" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34629414" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Interferon Gamma Release Assay and Tuberculin Skin Test Performance in Pregnant Women Living With and Without HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34517050" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Stages of pregnancy and HIV affect diagnosis of tuberculosis infection and Mycobacterium tuberculosis (MTB)-induced immune response: Findings from PRACHITi, a cohort study in Pune, India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11444726" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Drug treatment for tuberculosis during pregnancy: safety considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2495549" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Isoniazid hepatitis among pregnant and postpartum Hispanic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31577875" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29393655" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15902136" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Postpartum follow-up of a positive purified protein derivative (PPD) among an indigent population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30067931" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9295239" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22157884" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34323955" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34323955" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20558626" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16704034" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2782741" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Twenty isoniazid-associated deaths in one state.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1736764" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Isoniazid-associated hepatitis deaths: a review of available information.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19250368" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Tuberculosis in pregnancy in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329197" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329197" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329197" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6367682" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Should women taking antituberculosis drugs breast-feed?</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
